Skip to content

The Glissonean versus Hilar Dissection Approach for Laparoscopic Major Hepatectomies in hepatocellular carcinoma patients: A Prospective, Randomized Trial

The Glissonean versus Hilar Dissection Approach for Laparoscopic Major Hepatectomies in hepatocellular carcinoma patients: A Prospective, Randomized Trial

Status
Recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR-IOR-17013077
Enrollment
Unknown
Registered
2017-10-22
Start date
2017-11-01
Completion date
Unknown
Last updated
2017-11-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

hepatocellular carcinoma

Interventions

Glissonean Approach:Glissonean Approach for laparoscopic hepatectomy
Hilar Dissection Approach:Hilar Dissection Approach for laparoscopic hepatectomy

Sponsors

West China Hospital, Sichuan University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Hepatocellular carcinoma was diagnosed before surgery; 2. No extrahepatic metastasis by preoperative imaging examination; 3. Aged 18 to 75 years old; 4. HCC patients with BCLC stage 0 or stage A; 5. Liver function of Child-Pugh A; 6. Patients who agree to sign the informed consent; 7. Laparoscopic major hepatectomy(more than three hepatic segments).;Inclusion criteria: 1. Hepatocellular carcinoma was diagnosed before surgery; 2. No extrahepatic metastasis by preoperative imaging examination; 3. Aged 18 to 75 years old; 4. HCC patients with BCLC stage 0 or stage A; 5. Liver function of Child-Pugh A; 6. Patients who agree to sign the informed consent; 7. Laparoscopic major hepatectomy(more than three hepatic segments).;Inclusion criteria: 1. Hepatocellular carcinoma was diagnosed before surgery; 2. No extrahepatic metastasis by preoperative imaging examination; 3. Aged 18 to 75 years old; 4. HCC patients with BCLC stage 0 or stage A; 5. Liver function of Child-Pugh A; 6. Patients who agree to sign the informed consent; 7. Laparoscopic major hepatectomy(more than three hepatic segments).;Inclusion criteria: 1. Hepatocellular carcinoma was diagnosed before surgery; 2. No extrahepatic metastasis by preoperative imaging examination; 3. Aged 18 to 75 years old; 4. HCC patients with BCLC stage 0 or stage A; 5. Liver function of Child-Pugh A; 6. Patients who agree to sign the informed consent; 7. Laparoscopic major hepatectomy(more than three hepatic segments).;Inclusion criteria: 1. Hepatocellular carcinoma was diagnosed before surgery; 2. No extrahepatic metastasis by preoperative imaging examination; 3. Aged 18 to 75 years old; 4. HCC patients with BCLC stage 0 or stage A; 5. Liver function of Child-Pugh A; 6. Patients who agree to sign the informed consent; 7. Laparoscopic major hepatectomy(more than three hepatic segments).

Exclusion criteria

Exclusion criteria: (1) Multiple histories of upper abdominal surgery or recurrent hepatocellular carcinoma; (2) Other organs except for gall bladder are involved during surgery; (3) Patients who accompany with severe organic diseases of heart, lung, kidney, et al.;Exclusion criteria: (1) Multiple histories of upper abdominal surgery or recurrent hepatocellular carcinoma; (2) Other organs except for gall bladder are involved during surgery; (3) Patients who accompany with severe organic diseases of heart, lung, kidney, et al.;Exclusion criteria: (1) Multiple histories of upper abdominal surgery or recurrent hepatocellular carcinoma; (2) Other organs except for gall bladder are involved during surgery; (3) Patients who accompany with severe organic diseases of heart, lung, kidney, et al.;Exclusion criteria: (1) Multiple histories of upper abdominal surgery or recurrent hepatocellular carcinoma; (2) Other organs except for gall bladder are involved during surgery; (3) Patients who accompany with severe organic diseases of heart, lung, kidney, et al.;Exclusion criteria: (1) Multiple histories of upper abdominal surgery or recurrent hepatocellular carcinoma; (2) Other organs except for gall bladder are involved during surgery; (3) Patients who accompany with severe organic diseases of heart, lung, kidney, et al.

Design outcomes

Primary

MeasureTime frame
1,3,5 year overall survival;

Secondary

MeasureTime frame
perioperative complications;operation time;blood loss;hospital stay;

Countries

China

Contacts

Public ContactWei Yonggang;Wei Yonggang;Wei Yonggang;Wei Yonggang;Wei Yonggang ;;;;

West China Hospital, Sichuan University;West China Hospital, Sichuan University;West China Hospital, Sichuan University;West China Hospital, Sichuan University;West China Hospital, Sichuan University

wyonggang688@163.com;wyonggang688@163.com;wyonggang688@163.com;wyonggang688@163.com;wyonggang688@163.com+86 18980602268;+86 18980602268;+86 18980602268;+86 18980602268;+86 18980602268

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Apr 24, 2026